ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Benzinga03-26 22:04

ImmunityBio Inc. (NASDAQ:IBRX) shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The company announced that the Independent Data Monitoring Committee (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622154866?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/26/San-Diego--Ca--Usa---July-9--2022-Immuni.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-03-26 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622154866","market":"hk","top_or_hot":-1,"title":"ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check","media":"Benzinga","content":"<div>\n<p>ImmunityBio Inc. (NASDAQ:IBRX) shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%.\nThe company announced that the Independent Data Monitoring Committee (...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ImmunityBio Inc. (NASDAQ:IBRX) shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%.\nThe company announced that the Independent Data Monitoring Committee (...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PW","symbol_name":"Power REIT","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check","article_id":"2622154866","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/26/San-Diego--Ca--Usa---July-9--2022-Immuni.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51482773/immunitybio-lead-bladder-cancer-drug-trial-clears-power-check","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622154866","pubTimestamp":1774533840,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"ImmunityBio stock dips despite Anktiva trial validation, FDA ad warning, and bullish analyst targets amid strong year-to-date gains.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PW":"Power REIT","BCG":"Binah Capital Group Inc","IBRX":"ImmunityBio, Inc.","CR":"crane","BK4139":"生物科技","BK4084":"特种房地产投资信托","BK4234":"特殊用途房地产信托","BK4161":"工业机械","BK4135":"资产管理与托管银行"},"translate_title":"ImmunityBio牵头膀胱癌药物试验通过能力检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PW":1.5,"CR":1,"BCG":1,"IBRX":1},"content_text":"ImmunityBio Inc. (NASDAQ:IBRX) shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%.\nThe company announced that the Independent Data Monitoring Committee (IDMC) confirmed the statistical power of its pivotal randomized trial for Anktiva.\nThe IDMC’s review indicated that no additional enrollment is needed beyond the current 366 participants, confirming that the study is adequately powered to detect a clinically meaningful difference in complete response (CR) rates.\nThe trial, known as QUILT-2.005, is evaluating Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary disease.\nUpon reaching this pre-specified 50% evaluable threshold, a planned interim analysis by an IDMC was initiated per protocol to verify that the 366 patients enrolled to date provide sufficient statistical power to detect the pre-specified clinically meaningful difference in CR rate between the two arms.\nIn the context of this trial, ImmunityBio has highlighted the promising results from earlier phases, where patients showed a prolonged duration of complete remission.\nThe company plans to submit a supplemental Biologics License Application based on the final data analysis in 2026.\nAdditionally, the company is advancing its phase 1 trial (QUILT-3.076). It will combine M-ceNK cells with Anktiva, which has demonstrated promising antitumor activity across multiple cancer types.\nOn Tuesday, the U.S. Food and Drug Administration (FDA) determined that a direct-to-consumer TV ad and podcast promoting Anktiva were false or misleading and misbranded the drug under federal law. \nThe FDA said the materials made unsupported claims that Anktiva could cure or prevent cancer and suggested effectiveness beyond its approved use, including treatment for multiple cancers and use as a standalone therapy. \nLast week, the National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for Bladder Cancer and included Anktiva plus BCG for BCG-unresponsive NMIBC with papillary-only disease.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $12.57. Recent analyst moves include:\nTop ETF Exposure\nIBRX Stock Price Activity: ImmunityBio shares were down 2.44% at $7.87 during premarket trading on Thursday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622154866","isCrawlerRequest":true}